Many breast cancer drugs block estrogen receptors inside cancer cells. Blocking the receptors early in disease progression staves off metastasis. But most patients with advanced disease eventually ...

This chapter of this background paper describes the Food and Drug Administration’s (FDA) statutory authority and responsibility for new therapeutics, FDA programs begun as a result of legislative ...

A growing body of research has examined the IRA’s implications for pharmaceutical innovation. Much of this literature has focused on the potential impact on the number of new drug launches, 5, 6 but ...

Curanex believes the combination of major unmet need, limited treatment options and growing clinical recognition supports a ...

The 2026 PSMA & Beyond conference featured a clinical development session and presentation by Dr. William Maguire discussing regulatory considerations related to PSMA PET imaging in clinical trials.

The post HYD Pioneers New Research Revealing Systemic Role of Deuterium-Depleted Water in Cancer Therapy appeared first on ...

NCI has played, and should continue to play, an important role in the development of new cancer therapeutics. That role has changed and will continue to evolve as the basic science underlying cancer ...

SAN FRANCISCO--(BUSINESS WIRE)--Noetik, an AI drug discovery company leveraging machine learning and proprietary human data to develop precision therapeutics in immuno-oncology, announced today that ...

Bissan Al-Lazikani (left) is a Professor of Genomic Medicine and Director of Therapeutics Data Science at The University of Texas MD Anderson Cancer Center (Houston, TX, USA), where she heads an ...

Shares of Oric Pharmaceuticals sank 40% Wednesday after the cancer biotech reported study results that were positive--but not positive enough for Wall Street. In an early-stage trial, Oric’s prostate- ...